logo
Plus   Neg
Share
Email

Bristol-Myers Squibb: Phase 3 Study With Opdivo Fails To Meet Primary Endpoint

Bristol-Myers Squibb Company (BMY) said CheckMate-459, a Phase 3 study evaluating Opdivo versus sorafenib as a first-line treatment in patients with unresectable hepatocellular carcinoma, failed to achieve statistical significance for primary endpoint of overall survival. No new safety signals were observed with Opdivo from the trial.

Bristol-Myers said the results from the Phase 3 trial showed a clear trend towards improvement in overall survival for patients treated with Opdivo compared to current standard of care.

Opdivo is currently under study across multiple settings and lines of therapy for hepatocellular carcinoma.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Latam Airlines Group SA, one of the largest air carrier in South America, has filed for bankruptcy protection in New York amid the ongoing Covid-19 pandemic, which has grounded flights worldwide. This Chapter 11 filing allows Latam to work with its creditors and other stakeholders to reduce its debt,... Pizza Hut said it is giving away 500,000 free pizzas to 2020 graduates in the Unites States. The pizza chain, owned by Yum! Brands, offers one free medium 1-topping pizza to all diploma/degree earning individuals until supplies last. The company is partnering with America's dairy farmers for the offer, which can be claimed until Thursday and redeemed until June 4. Merck & Co. Inc. on Tuesday announced deals, including an acquisition and two collaborations that will enable the U.S. drugmaker to join the race to develop coronavirus vaccines and drugs. Shares of Merck were rising almost 4 percent in the pre-market. Merck said it has agreed to acquire privately-held Themis, an Austria-based company focused on vaccines and immune-modulation therapies.
Follow RTT